Within each age, we further divide the population into low risk and high risk for influenza complications, with high risk being identified by existing medical conditions such as asthma, heart disease, and pregnancy. The proportion high risk by age is given in Table S1 .1 [3] . (Where the age groups for the proportion at high risk do not line up with our model age groups, we assumed that people are distributed uniformly within the model age groups. E.g. we assume that from the age group 15-19, 60% are under 18 and 40% are over 18.)
Each of the age-risk groups is then stratified by infection status. Let S LUa (t), E LUa (t), I LUa (t), and R LUa (t) be the respective numbers of unvaccinated low-risk susceptible, latent, infectious, and recovered people in age groups a = 1, 2, . . . , 17. Let S HUa (t), E HUa (t), I HUa (t), and R HUa (t) be defined similarly, but for unvaccinated high-risk people. Now, let S LVa (t), E LVa (t), I LVa (t), R LVa (t), S HVa (t), E HVa (t), I HVa (t), R HVa (t) be defined similarly for vaccinated people. Compiled by the MIDAS High-Risk Segmentation Group [3] . High risk for influenza complications is defined as having a chronic condition that is indications receiving influenza vaccine, having an immunocompromised condition, or being pregnant. For adults, the chronic conditions that indicate vaccination are: current asthma, chronic bronchitis, emphysema, coronary heart disease, angina, heart attack, diabetes, stroke, weak kidney, epilepsy, cerebral palsy, movement disorders, and muscular dystrophies [4] . For children, these chronic conditions are: current asthma, congenital heart disease, ever diabetes, Down syndrome, ever cerebral palsy, ever muscular dystrophy, ever cystic fibrosis, ever sickle cell anemia, and seizures in past 12 months [4] . For children under 6 months, birth weight less than 1500 gm is also included [4] . Immunocompromised conditions are: cancer in the past 3 years [4] , HIV/AIDS [5] , dialysis [6] , and having had an organ transplant [7] . Pregnancy is also included [4] . (S1.1q)
Here φ aα is the number of contacts between a person in age group a with people in age group α, β is the probability of infection for a susceptible person who has contact with an infectious person, and σ a is the relative susceptibility of people in age group a. The relative susceptibility incorporates the potential for older people to have some immunity to the current 2009 H1N1 strain due to exposure to a similar virus in the distant past. The total population size is N :
The demographic effects of aging, birth, and death by causes not related to influenza are not included because we only model one influenza season, where these demographic effects are small. The epidemic is initiated with the entire population unvaccinated, with one person of each age infectious, and the remaining population susceptible.
That is
where N a is the number of people of age a (from the estimated 2007 US population [2] ) and P Ha is the proportion of age group a who are high risk (Table S1 .1).
Numerical solution of the model differential equations was done using the LSODA routine [8] .
S1.1.2 Basic Reproductive Number
The basic reproductive number (R 0 ) of model (S1.1) was calculated using the next-generation matrix ( [1, 9, 10] ). No closed form expression is available for R 0 for model (S1.1): rather, it is given by the leading eigenvalue of a matrix depending on the model parameters.
Consider the case when no one in the population has been exposed to the pathogen and there is no vaccination. Define the sub-matrices
(S1.3d)
Here, δ aα is the Dirac delta:
Now define the matrices
where ρ(M) is the largest magnitude of the eigenvalues of the matrix M. This calculation of R 0 is easily extended to include a population with both unvaccinated and vaccinated people.
S1.1.3 Optimal Vaccine Allocation
A vaccine delivery schedule is a list of amounts of vaccine available (v r ) and the time (in days) at which they are available (t r ), for r = 1, 2, . . . , R, for a total of R batches of vaccine availability. For example, a schedule with 45 million doses available on day t 1 and 20 million doses available each week thereafter for 3 weeks would have t 1 = t 1 , v 1 = 45 000 000, t 2 = t 1 + 7, v 2 = 20 000 000, t 3 = t 1 + 14, v 3 = 20 000 000, and t 4 = t 1 + 21, v 4 = 20 000 000.
Let p Lra L be the proportion of the vaccine that is available at time t r that is given to low-risk people in age group a L and p Hra H be the proportion given to high-risk people in age group a H ; these are the control variables. New age groups, a L = 1, 2, . . . , A L and a H = 1, 2, . . . , A H have been introduced to allow for vaccine policies that have different age groups than those in model (S1.1) itself. In particular, we will consider that we wish to find the best way to distribute vaccine to the 5 low-risk age groups (A L = 5) 0-4, 5-17, 18-44, 45-64, and 65+ and a single group for high-risk people of all ages (A H = 1). The factor G Laa L is the fraction of low-risk people in model age group a who are also in vaccination age group a L and G Haa H is defined similarly for highrisk people: these convert between the age groups used in model (S1.1) and those used as the basis for vaccine distribution. For our age groups, these are since high-risk people of all ages are combined into one vaccination group. Then, given the proportions vaccinated in the vaccination age groups, p Lra L and p Hra H , the quantities
are the proportions vaccinated in the model age groups. We take vaccination to only be done to unvaccinated susceptible people and to instantaneously protect people, so that the state variables change discontinuously at t = t r :
with the other state variables remaining the same. The cumulative number of infections at time T is
for unvaccinated low-risk, unvaccinated high-risk, vaccinated low-risk, and vaccinated high-risk people, respectively. The middle terms in equations (S1.10), those with the summations, account for the change in vaccination status when vaccine is distributed. Here
are the numbers of people summed over infection status. The cumulative number of deaths is
where N a is the total number of people in age group a
We will minimize, at the end time T , the objective function that is either total deaths
or total hospitalizations 15) where
are the numbers of infections in age group a to low-risk and high-risk people, respectively, and c La and c Ha are the case hospitalizations for low-risk and high-risk people in age group a. Note that here we have assumed that the risk of hospitalization is independent of vaccination status. The problem is, given the starting time (t 0 ), the end time (T ) and the vaccine delivery schedule (t 1 , t 2 , . . . , t R and v 1 , v 2 , . . . , t R ), find the p Lra L and p Hra H that minimize objective function (S1.14) or (S1.15), subject to the feasibility conditions
the latter of which ensures that the number of vaccines used is below the number available; the initial conditions (S1.2) at t = t 0 ; the differential equations (S1.1) on t k < t ≤ t k+1 for k = 0, 1, 2, . . . , R, where t R+1 = T ; and the jump conditions (S1.9) at t = t r for r = 1, 2, . . . R. For a given vaccine distribution schedule, the optimal vaccine allocations were found numerically using the constrained optimization by linear approximation (COBYLA) algorithm [11] , run 3 times with random initial vaccination levels. We took the optimum to be the result with the smallest value of the objective function among these 3 runs.
S1.2 Parameter Values
The model epidemiological parameters are listed in Table S1 .2. The latent period, the time between becoming infected and becoming infectious, has not been estimated directly, but the incubation period, the time between becoming infected and becoming symptomatic, has [12, 13] . We assumed that a person becomes infections 1 day before becoming symptomatic [12] , so that the latent period is 1 day shorter than the incubation period. Analysis of the first 11 cases of 2009 H1N1 documented by the U.S. Centers for Disease Control and Prevention found a median incubation period of 3 days [13] . The infectious period is not known for 2009 H1N1, so we have taken it to be 7 days as the upper end of the range from seasonal influenzas [12] .
In addition, we parametrized the contact matrix (φ aα ), which describes the number of potentially transmitting contacts per day between a person in age group a and people in age group α, as in Medlock & Galvani [1] , using survey-based data [14] . In our model, the only impact of being in the high-risk group was an increased risk of averse outcomes, death and hospitalization, from influenza infection. We assumed that high-risk people are 9 times more likely to die from an infection and 3 times more likely to be hospitalized. These risk ratios are consistent with those found for seasonal influenzas [see 17, and references therein].
We assumed that the empirical case mortality (d a , Table S1 .2) was to people with the same proportion of the risk groups as the overall population (Table S1 .1) and, of course, to all unvaccinated people. The case mortality for low-risk, unvaccinated people is then
Then the case mortality in terms of the model parameters recovery rate (γ) and death rate for low-risk, unvaccinated people (ν LUa ), is
Therefore,
This is the death rate for low-risk, unvaccinated people. The case mortality for low-risk, vaccinated people is then reduced by the vaccine efficacy against death (δ a ), giving
We assume high-risk people have a 9 times higher risk of death (Table S1. 3), so that the death rates are
Note here that we have assumed that the vaccine efficacy against death reduces the case mortality by the same relative amount in both low-risk and high-risk people. Similarly, we took the empirical case hospitalization (c a ) to be to people in the same proportion of the risk groups as the overall population. Then the model case hospitalization for low-risk people (c La ) is
and the case hospitalization for high-risk people to be 3 times higher (Table S1.3), c Ha = 3c La . The one remaining parameter, the probability of transmission given a suitable contact (β), was then chosen so that the model's basic reproductive number (in the absence of vaccination) had a proscribed value. We considered R 0 = 1.2, 1.4, 1.7, and 2.0. [17] . See text for more. Figure S1 .1 shows epidemic curves for different age groups for an outbreak with R 0 = 1.4 and no vaccination. The transmission model has 17 age groups: the 17 age groups were combined into just 5 age groups to simplify the figure.
S1.3 Results
To simulate the ongoing 2009 H1N1 influenza pandemic, we took the estimate of 1 million cumulative cases on 1 August 2009 [19] and the vaccine delivery schedule as 45 million doses on 15 October 2009 and 20 million doses each week thereafter. We compared vaccine delivery schedules with only the first batch of 45 million doses; with two batches, a 45 million dose batch and then a 20 million dose batch; with three batches, 45 million dose batch and then two 20 million dose batches; and so on, up to a 45 million dose batch followed by eight 20 million dose batches. In addition, we also compared two more delivery schedules, a single batch of 125 million doses on 15 October and a single batch of 125 million doses before the outbreak began. For each of these vaccine delivery schedules, we found the optimal age-and risk-dependent allocation that minimized either deaths or hospitalizations (Figures 1, 2 , & S1.2-S1.15).
Figures S1.8-S1.15 show the optimal allocations of multiple batches of vaccine for a given number of batches. Of particular interest is that the optimal allocations for multiple batches cannot be found by iteratively finding the optimal allocation for the first batch, then for the second batch given the allocation for the first batch, and so on. The optimal allocation in each batch depends on the total number of batches. For example, for R 0 = 1.2 and deaths averted ( Figure S1.8) , the optimal allocation when there are 2 total batches of vaccine includes vaccinating some 18-44 year olds in the second batch, while, when there are 3 total batches of vaccine, vaccinating 18-44 year olds is not optimal. 
